3MJ1
X-ray crystal structure of ITK complexed with inhibitor RO5191614
Summary for 3MJ1
| Entry DOI | 10.2210/pdb3mj1/pdb |
| Related | 3MIY 3MJ2 |
| Descriptor | Tyrosine-protein kinase ITK/TSK, 7-[(4-methylpiperazin-1-yl)methyl]-4-[(3-methyl-1H-pyrazol-5-yl)amino]-2-(tetrahydro-2H-pyran-4-yl)phthalazin-1(2H)-one (3 entities in total) |
| Functional Keywords | helix c-out, transferase |
| Biological source | Homo sapiens (human) |
| Cellular location | Cell membrane (By similarity): Q08881 |
| Total number of polymer chains | 1 |
| Total formula weight | 30553.96 |
| Authors | Kuglstatter, A.,Villasenor, A.G. (deposition date: 2010-04-12, release date: 2010-06-30, Last modification date: 2023-09-06) |
| Primary citation | Kutach, A.K.,Villasenor, A.G.,Lam, D.,Belunis, C.,Janson, C.,Lok, S.,Hong, L.N.,Liu, C.M.,Deval, J.,Novak, T.J.,Barnett, J.W.,Chu, W.,Shaw, D.,Kuglstatter, A. Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation. Chem.Biol.Drug Des., 76:154-163, 2010 Cited by PubMed Abstract: IL-2-inducible T cell kinase plays an essential role in T cell receptor signaling and is considered a drug target for the treatment of Th2-mediated inflammatory diseases. By applying high-throughput protein engineering and crystallization, we have determined the X-ray crystal structures of IL-2-inducible T cell kinase in complex with its selective inhibitor BMS-509744 and the broad-spectrum kinase inhibitors sunitinib and RO5191614. Sunitinib uniquely stabilizes IL-2-inducible T cell kinase in the helix C-in conformation by inducing side chain conformational changes in the ATP-binding site. This preference of sunitinib to bind to an active kinase conformation is reflective of its broad-spectrum kinase activity. BMS-509744 uniquely stabilizes the activation loop in a substrate-blocking inactive conformation, indicating that structural changes described for Src family kinases are also involved in the regulation of IL-2-inducible T cell kinase activity. The observed BMS-509744 binding mode allows rationalization of structure-activity relationships reported for this inhibitor class and facilitates further structure-based drug design. Sequence-based analysis of this binding mode provides guidance for the rational design of inhibitor selectivity. PubMed: 20545945DOI: 10.1111/j.1747-0285.2010.00993.x PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.72 Å) |
Structure validation
Download full validation report
